Menu Search
Equities

Sonnet Biotherapeutics Holdings Inc

H3D:BER

Sonnet Biotherapeutics Holdings Inc

Actions
  • Price (EUR)0.184
  • Today's Change0.00 / 0.00%
  • Shares traded--
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of Sep 01 2023 07:09 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Sonnet Biotherapeutics Holdings Inc had revenues fall -57.76% from 349.94k to 147.81k, though the company grew net income from a loss of 29.72m to a smaller loss of 18.83m.
Gross margin--
Net profit margin-14,287.67%
Operating margin-14,271.32%
Return on assets-100.88%
Return on equity-264.57%
Return on investment-255.30%
More ▼

Cash flow in USDView more

In 2023, cash reserves at Sonnet Biotherapeutics Holdings Inc fell by 778.62k. Cash Flow from Financing totalled 21.01m or 14,211.81% of revenues. In addition the company used 21.34m for operations while cash used for investing totalled 443.25k.
Cash flow per share-2.06
Price/Cash flow per share--
Book value per share0.5017
Tangible book value per share0.5017
More ▼

Balance sheet in USDView more

Sonnet Biotherapeutics Holdings Inc uses little or no debt in its capital structure.
Current ratio1.65
Quick ratio--
Total debt/total equity0.00
Total debt/total capital0.00
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.